Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 11 for:    Heplisav-B | Hepatitis B

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B (BEe-HIVe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04193189
Recruitment Status : Recruiting
First Posted : December 10, 2019
Last Update Posted : April 13, 2021
Sponsor:
Collaborator:
Dynavax Technologies Corporation
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.

Condition or disease Intervention/treatment Phase
HIV Infection Hepatitis B Biological: HEPLISAV-B Biological: ENGERIX-B Phase 3

Detailed Description:

This phase III/IV study will evaluate the response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders (Group A) and individuals who are naïve to HBV vaccination (Group B).

Group A (HBV vaccine non-responders)

The study is designed as an open-label three-arm study to evaluate whether:

  1. HEPLISAV-B vaccination given as a two-dose series achieves non-inferior seroprotection response (SPR) compared to standard dose ENGERIX-B.
  2. HEPLISAV-B vaccination given as a three-dose series achieves superior SPR proportion compared to standard dose ENGERIX-B.

Participants are randomized in 1:1:1 ratio to the following study arms, stratified by sex at birth (male vs. female) and diabetes diagnosis status (yes vs. no):

  • Arm 1: Two doses of HEPLISAV-B at weeks 0 and 4.
  • Arm 2: Three doses of HEPLISAV-B at weeks 0, 4, and 24.
  • Arm 3: Three doses of ENGERIX-B at weeks 0, 4, and 24.

The target sample size in Group A is 561 participants, 187 participants in each arm.

Group B (Naïve to HBV vaccination)

Group B study is a single arm evaluation of vaccine response and safety of three doses of HEPLISAV-B. The target sample size is 73 participants.

All participants will remain on their non-study-provided antiretroviral therapy (ART) throughout the study. Participants in both groups will attend several study visits through Week 72. Visits may include physical examinations and blood collection. For 7 days after each vaccination, participants will record temperature and any reactions they have to the vaccine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 634 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
Actual Study Start Date : December 14, 2020
Estimated Primary Completion Date : March 22, 2023
Estimated Study Completion Date : March 22, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A, Arm 1: HEPLISAV-B (two injections)
Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
Biological: HEPLISAV-B
Administered by IM injection

Experimental: Group A, Arm 2: HEPLISAV-B (three injections)
Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
Biological: HEPLISAV-B
Administered by IM injection

Experimental: Group A, Arm 3: ENGERIX-B (three injections)
Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
Biological: ENGERIX-B
Administered by IM injection

Experimental: Group B: HEPLISAV-B (three injections)
Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
Biological: HEPLISAV-B
Administered by IM injection




Primary Outcome Measures :
  1. Seroprotection response defined as hepatitis B virus surface antibody (HBsAb) ≥10 mIU/mL [ Time Frame: Week 12 in Group A, Arm 1, Week 28 in Group A, Arms 2 and 3 and in Group B ]
  2. Occurrence of Adverse events (AEs) [ Time Frame: From vaccination initiation to study discontinuation (Week 72 or premature discontinuation) ]
    DAIDS AE Grading Table (Version 2.1) will be used.


Secondary Outcome Measures :
  1. Seroprotection response defined as HBsAb ≥10 mIU/mL [ Time Frame: Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72 ]
  2. HBsAb titer [ Time Frame: Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72 ]
  3. Occurrence of Grade ≥2 AEs within 4 weeks after each injection [ Time Frame: From vaccination initiation to Week 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria, Groups A and B

  • HIV-1 infection
  • On current HIV-1 antiretroviral therapy (ART)
  • CD4+ T-cell count ≥100 cells/mm^3
  • HIV-1 RNA <1000 copies/mL

Inclusion Criteria, Group A only

  • Serum Hepatitis B antibody <10 mlU/mL, non-reactive (negative), or indeterminate
  • Documentation of HBV vaccination >168 days prior to study entry

Inclusion Criterion, Group B only

  • Serum Hepatitis B antibody non-reactive (negative) within 45 days prior to study entry

Exclusion Criteria, Groups A and B

  • Infection or prior exposure to HBV
  • Serum HBsAb level ≥10 mlU/mL or positive at screening or any other time prior to screening
  • Presence of any active or acute AIDS-defining opportunistic infections
  • Solid organ transplantation
  • History of ascites, encephalopathy, or variceal hemorrhage
  • Diagnosis of chronic kidney disease (CKD) stage G4
  • Cancer diagnosis within 5 years
  • Currently receiving chemotherapy
  • Chronic use and/or receipt of systemically administered immunosuppressive
  • Known allergy/sensitivity or any hypersensitivity to any HBV vaccine or yeast
  • Active, serious infection other than HIV-1
  • Receipt of any inactivated virus vaccine within 14 days
  • Receipt of any of the following within 45 days prior to study entry:

    • Live virus vaccine
    • Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)
    • Any other investigational medicinal agent
  • Receipt of immunoglobulin or blood products within 90 days prior to study entry
  • Receipt of an injection of DNA plasmids or oligonucleotides within 60 days prior to study entry

Exclusion Criteria, Group A only

  • Hepatitis B virus vaccination ≤168 days prior to study entry
  • Receipt of HEPLISAV-B vaccine at any time prior to study entry

Exclusion Criterion, Group B only

  • Known HBV vaccination prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04193189


Locations
Show Show 33 study locations
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Dynavax Technologies Corporation
Investigators
Layout table for investigator information
Study Chair: Kenneth E. Sherman, MD, PhD Cincinnati CRS
Study Chair: Kristen Marks, MD Weill Cornell Chelsea CRS
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04193189    
Other Study ID Numbers: ACTG A5379
38569 ( Registry Identifier: DAIDS-ES Registry Number )
First Posted: December 10, 2019    Key Record Dates
Last Update Posted: April 13, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie results in the publication, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
Access Criteria:
  • With whom?

    • Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
  • For what types of analyses?

    • To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
  • By what mechanism will data be made available?

    • Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis
Liver Diseases
Digestive System Diseases
Virus Diseases
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Viral, Human